ARWR
Arrowhead Pharmaceuticals, Inc.
ARWR lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ARWR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
ARWR's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ARWR PE Valuation
ARWR has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ARWR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ARWR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ARWR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.11 | -$5.10 |
| Q2 2026 | -$2.18 | -$0.92 |
| Q1 2026 | -$2.08 | -$0.70 |
| Q4 2025 | $1.60 | +$6.75 |
| Q3 2025 | -$0.01 | +$4.99 |
| Q2 2025 | -$1.26 | +$3.40 |
| Q1 2025 | -$1.38 | +$2.86 |
| Q4 2024 | -$5.15 | -$2.38 |
ARWR lost $5.11 per share over the past year, and its loss has widened in each of the last three quarters.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ARWR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.8M | -85% |
| Q2 2026 | $75.3M | +171% |
| Q1 2026 | $73.7M | -86% |
| Q4 2025 | $264M | +10461% |
| Q4 2024 | $2.5M | -30% |
| Q4 2023 | $3.6M | -94% |
| Q3 2023 | $16.1M | -49% |
| Q2 2023 | $15.8M | -51% |
ARWR's revenue has slid since its 2025 peak: $38M last quarter, down 85% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1155% | -1173 points |
| Q2 2026 | -226% | +370 points |
| Q1 2026 | -192% | -262 points |
| Q4 2025 | 15% | +6472 points |
| Q3 2025 | 17% | N/A |
| Q2 2025 | -596% | N/A |
| Q1 2025 | 70% | N/A |
| Q4 2024 | -6456% | -2611 points |
ARWR's operating margin was −1155% last quarter, down 1172 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ARWR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ARWR on profitability, with a higher operating margin.
ARWR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$195.8M | -1606% |
| Q2 2026 | -$181.3M | -$24.2M |
| Q1 2026 | $81.9M | -82% |
| Q4 2025 | $11.3M | +$165.1M |
| Q3 2025 | $13M | +$174.5M |
| Q2 2025 | -$157.1M | -$27.2M |
| Q1 2025 | $454.8M | +$581.2M |
| Q4 2024 | -$153.8M | +$32.7M |
ARWR has burned cash in most quarters: −$284M over the past year, against $157M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ARWR on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARWR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -1.7M shares |
| 1 year | +5.9% | +7.9M shares |
| 3 years | +33% | +34.9M shares |
| 5 years | +37% | +37.9M shares |
| Available history | +46% | +44.5M shares |
ARWR has 142M diluted shares, up 5.9% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ARWR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ARWR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q1 2020 | -51.3x | Net Cash |
| Q4 2019 | -9.3x | Net Cash |
ARWR has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over ARWR on leverage, with a lower net debt burden relative to earnings.
ARWR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.8 | Oversold |
| Stochastic | 6.6 | Oversold |
ARWR's weekly RSI is 30 (oversold) and its Stochastic is 7 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ARWR PE vs Healthcare Sector
| Metric | ARWR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ARWR has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ARWR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.0 | 20% below |
| 20 week MA | $73.0 | 35% below |
| 50 week MA | $70.0 | 33% below |
| 100 week MA | $46.1 | 2.3% above |
| 200 week MA | $37.1 | 27% above |
ARWR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ARWR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $64.9 | $84.2 | +30% |
| 2021 | $84.2 | $70.3 | -17% |
| 2022 | $70.3 | $38.3 | -45% |
| 2023 | $38.3 | $30.6 | -20% |
| 2024 | $30.6 | $19.0 | -38% |
| 2025 | $19.0 | $70.2 | +270% |
| 2026 YTD | $70.2 | $47.2 | -33% |
ARWR has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.